Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND-1 Long Term Follow Up
2010-021259-22Phase 3Terminated
- Sponsor
- TolerX, Inc.
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetes mellitus type 1 (T1D) comparing Prior otelixizumab with Prior placebo (2 arms). Started Nov 2010; status: terminated.
02
Drugs
otelixizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2010-021259-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021259-22.